Osiris Therapeutics Completes Enrollment Of Stem Cell Trial For The Treatment Of Heart Attacks
Links shared publicly online about this topic.
- 464total visits
Osiris Therapeutics Completes Enrollment Of Stem Cell Trial For The Treatment Of Heart Attacks
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L), an adult mesenchymal stem cell t
View full resource at medicalnewstoday.com
Tags: Heart, Heart Disease, Heart Attack, Thrombotic Event, Stem Cell, Phase 2 Clinical Trial, Clinical Trial
Most Recently Shared on March 4, 2011 at 11:27 am By:
MedicalNewsToday: Osiris Therapeutics Completes Enrollment Of Stem Cell Trial For The: http://bit.ly/f7X7O7 Full http://bit.ly/eT9EiX
Also Shared By:
Advertisement
MNT Cardiovascular
@mnt_cardiovasc
Osiris Therapeutics Completes Enrollment Of Stem Cell Trial For The Treatment Of Heart Attacks http://mnt.to/3RRs #cardiovascular
1 year ago...